Diffuse gliomas with FGFR3::TACC3 fusion have an intermediate prognosis, with poorer survival outcomes than IDH-mutant gliomas but superior outcomes compared to FGFR3::TACC3-negative glioblastomas [7]. This evidence concerns the gene TACC3 and central nervous system cancer.